The GATHER2 phase 3 clinical trial of Zimura for the treatment of geographic atrophy met its primary endpoint and demonstrated a favorable safety profile, according to a press release from Iveric Bio.
GATHER2, the second phase 3 trial of Zimura (avacincaptad pegol), enrolled 448 international participants who were randomly assigned to receive either an intravitreal injection of Zimura 2 mg or sham monthly for 12 months.
The prespecified primary endpoint of mean rate of growth (slope) in geographic atrophy (GA) area was met, with a 14.3% reduction over 12 months (Read more...)